Free Testosterone Test for Women: When to Order It and What the Results Actually Tell You

What Free Testosterone Actually Measures

Free testosterone is the portion of circulating testosterone that is not bound to sex hormone-binding globulin (SHBG) or albumin. It circulates freely in the bloodstream and can enter cells directly.

About 44 to 76 percent of testosterone in women is tightly bound to SHBG, where it is biologically inactive. Another 20 to 40 percent binds loosely to albumin and may be partly available to tissues. Only 1 to 3 percent circulates as free testosterone, yet that fraction drives most androgen-dependent effects: libido, clitoral sensitivity, muscle protein synthesis, sebaceous gland activity, and body-hair growth.

Total testosterone captures all three fractions together. In many women, total T can sit within the lab reference range while free T is clinically high or low, simply because SHBG has shifted. The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women specifically notes that SHBG concentration is a key modifier of testosterone bioavailability and recommends measuring free or bioavailable testosterone when SHBG is known or suspected to be abnormal.

Why SHBG Changes So Much in Women

SHBG is not a fixed protein. It rises with:

• Combined oral contraceptives (ethinyl estradiol raises SHBG by two- to fourfold)
• Pregnancy (rises throughout gestation)
• Hyperthyroidism
• Liver disease (some forms)
• Anorexia or very low body weight

SHBG falls with:

• Insulin resistance and hyperinsulinemia (the PCOS connection)
• Obesity
• Hypothyroidism
• Glucocorticoid excess
• Androgenic progestins

A woman on a combined oral contraceptive who reports zero libido and profound fatigue may have a total testosterone of 35 ng/dL (perfectly "normal") while her free testosterone sits at 0.15 ng/dL because her SHBG has tripled. The total result alone would be falsely reassuring. Research published in the Journal of Sexual Medicine found that women who used oral contraceptives had SHBG levels four times higher than non-users, a change that persisted in some women for months after stopping the pill.

How the Lab Actually Calculates or Measures Free T

Two methods are used clinically:

1. Equilibrium dialysis. The gold standard. A blood sample is dialyzed against a buffer; only truly unbound testosterone passes through the membrane. The Endocrine Society designates this as the most reliable method for free testosterone measurement in women.

2. Calculated free testosterone. Uses total T, SHBG, and albumin in a validated formula (Vermeulen equation). Acceptable accuracy when equilibrium dialysis is unavailable. Most major reference labs (Quest, LabCorp) offer this calculation.

A third method, direct immunoassay for free testosterone, is widely available but consistently unreliable at the low concentrations found in women. A 2011 study in the Journal of Clinical Endocrinology and Metabolism showed direct analog immunoassays overestimated free testosterone in women by a factor of two to four compared with equilibrium dialysis. If your lab report uses a direct immunoassay and does not specify the method, ask your clinician whether the result should be confirmed.

When Your Clinician Should Order This Test

Free testosterone is not a routine screening lab. Order it when a specific clinical question cannot be answered by total testosterone alone.

Signs of Androgen Excess

Order free T (alongside total T and SHBG) when you have:

• New or worsening hirsutism (coarse terminal hair on the chin, upper lip, chest, abdomen, or inner thighs)
• Acne that persists beyond adolescence or returns in adulthood
• Female pattern hair loss (androgenic alopecia) at the crown and temples
• Clitoral enlargement (rare; warrants urgent evaluation)
• Irregular or absent periods with concurrent androgenic symptoms

ACOG Practice Bulletin 194 on polycystic ovary syndrome recommends biochemical androgen testing in women with signs of hyperandrogenism, and specifically notes that free testosterone or bioavailable testosterone may be more sensitive than total T in detecting mild hyperandrogenism.

Signs of Androgen Insufficiency

Low androgen symptoms in women are less well-defined but include:

• Reduced or absent sexual desire (not explained by relationship or mood factors)
• Diminished genital sensation
• Loss of the "mental energy" associated with motivation and drive
• Unexplained fatigue in conjunction with normal thyroid, iron, and cortisol

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019), endorsed by The Menopause Society and 10 other international societies, states that testosterone measurement is required before initiating therapy and at follow-up to confirm levels remain within the physiological premenopausal range.

Monitoring Testosterone Therapy

If you are using testosterone therapy (cream, gel, or pellet), free testosterone is the preferred monitoring marker because exogenous testosterone raises SHBG less predictably than endogenous T. The Global Consensus Position Statement recommends checking levels 3 to 6 weeks after initiation of transdermal therapy and every 6 months once stable.

Adrenal or Ovarian Tumor Evaluation

When total testosterone exceeds 150 to 200 ng/dL or rises rapidly, imaging to exclude an androgen-secreting tumor is indicated regardless of free T. Free testosterone adds context but does not replace imaging in this setting.

Normal Free Testosterone Ranges by Life Stage

Reference ranges vary by assay method and laboratory. The values below reflect equilibrium dialysis or validated calculated methods as cited in peer-reviewed literature.

Reproductive Years (Approximately Ages 18 to 45)

The Endocrine Society guideline and mass spectrometry reference data published by Handelsman et al. In the Journal of Clinical Endocrinology and Metabolism place free testosterone in healthy premenopausal women at approximately 0.3 to 1.9 ng/dL (or 10 to 65 pmol/L in SI units). Free T peaks in the mid-20s and declines gradually across the reproductive years.

Free testosterone also fluctuates across the menstrual cycle. It rises modestly at ovulation and is slightly higher in the follicular phase than the luteal phase. Ideally, draw the sample in the early follicular phase (days 2 to 5) for the most reproducible result.

Perimenopause (Approximately Ages 40 to 52)

Testosterone production begins declining in the early 30s and continues through perimenopause. SHBG, however, may also shift as estradiol fluctuates, making the free T trajectory less predictable than total T. Some women experience a transient period of relative androgen excess in early perimenopause if estradiol drops faster than testosterone. Others notice a more pronounced free T decline that correlates with worsening sexual function.

A longitudinal study from the Study of Women's Health Across the Nation (SWAN) tracked testosterone and SHBG across the menopausal transition and found that total testosterone declined significantly over the 7-year follow-up, with free testosterone declining proportionally, but the rates varied widely between women of different racial and ethnic backgrounds.

Postmenopause

After the final menstrual period, ovarian androgen production does not stop entirely: the postmenopausal ovary continues to secrete testosterone under LH stimulation. However, free testosterone typically falls to 0.1 to 0.9 ng/dL in most postmenopausal women not using hormone therapy. SHBG may rise or fall depending on whether systemic estrogen therapy is used (oral estrogen raises SHBG; transdermal estrogen has minimal effect).

Adolescence

Free testosterone ranges in adolescent girls are not well standardized. Androgen levels rise during adrenarche and continue increasing through mid-puberty. Evaluating hyperandrogenism in adolescents requires caution: acne and irregular cycles are common in the first 2 years after menarche and do not necessarily indicate PCOS. ACOG recommends against diagnosing PCOS until at least 2 years post-menarche.

High Free Testosterone: What It Means and What Comes Next

A free testosterone above the upper limit of the premenopausal reference range (roughly <2.0 ng/dL on most assays) warrants a structured workup.

The Most Common Cause: PCOS

Polycystic ovary syndrome affects 8 to 13 percent of women of reproductive age, making it the most common cause of biochemical hyperandrogenism. The International Evidence-Based Guideline for the Assessment and Management of PCOS (2023) identifies free or calculated free testosterone as the preferred biochemical marker for hyperandrogenemia in suspected PCOS, noting that sensitivity is superior to total testosterone alone in women with borderline elevations.

In PCOS, insulin resistance suppresses hepatic SHBG production, which drives free T upward even when total T is only mildly elevated. This is why a woman with a total T of 45 ng/dL can have a free T at the upper limit of normal or above it.

Other Causes to Rule Out

| Condition | Distinguishing features | |---|---| | Congenital adrenal hyperplasia (non-classic) | Elevated 17-hydroxyprogesterone; family history | | Adrenal androgen-secreting tumor | Very high DHEAS; rapid virilization | | Ovarian androgen-secreting tumor | Unilateral ovarian mass; total T >150 ng/dL | | Cushing syndrome | Central obesity; hypertension; cortisol excess | | Exogenous androgen use | History; suppressed LH and FSH |

How to Lower Free Testosterone (When Clinically Indicated)

Lowering free T is appropriate when excess androgens drive symptoms or reproductive dysfunction. Strategies depend on cause:

• Combined oral contraceptives: Raise SHBG, binding more testosterone and reducing the free fraction. Pills containing drospirenone, norgestimate, or desogestrel have lower intrinsic androgenicity. A Cochrane review (2012) confirmed OCPs reduce free testosterone and improve hirsutism scores compared with placebo.
• Spironolactone: Blocks androgen receptors and reduces adrenal and ovarian androgen synthesis. Doses of 100 to 200 mg/day are commonly used. Requires reliable contraception (see pregnancy section below).
• Metformin: In insulin-resistant women with PCOS, metformin reduces hyperinsulinemia, which raises SHBG and lowers free T. Effect is modest compared with OCPs.
• Weight loss: A 5 to 10 percent reduction in body weight in women with obesity and PCOS can raise SHBG by 15 to 20 percent, meaningfully reducing free T without medication.
• Flutamide, bicalutamide: Anti-androgens reserved for refractory hirsutism; teratogenic and require strict contraception.

Low Free Testosterone: What It Means and What Comes Next

There is no universally accepted clinical threshold for "female androgen insufficiency." The Endocrine Society does not currently recommend a specific cutoff for diagnosing testosterone deficiency in women, because symptoms overlap substantially with those of estrogen deficiency, depression, and thyroid dysfunction.

The following framework helps contextualize a low free T result across life stages:

Step 1: Confirm the measurement method. A low result from a direct immunoassay should be repeated by equilibrium dialysis or calculated method before clinical decisions are made.

Step 2: Check SHBG. If SHBG is high (common with oral contraceptives, oral estrogen, or thyroid excess), low free T may reflect binding rather than deficient production.

Step 3: Assess symptoms specifically. Reduced sexual desire, diminished arousal, and low motivation that persist after optimizing sleep, thyroid, iron, and estrogen are the symptoms most consistently linked to low androgen in the evidence base.

Step 4: Consider life stage. A free T of 0.2 ng/dL is expected and normal in a 65-year-old postmenopausal woman not using testosterone therapy. The same result in a 30-year-old woman with hypothalamic amenorrhea warrants investigation of the HPG axis.

How to Raise Free Testosterone (When Clinically Indicated)

• Testosterone therapy (transdermal): The Global Consensus Position Statement supports the use of testosterone in postmenopausal women with hypoactive sexual desire disorder (HSDD) when estrogen deficiency has been addressed and other causes ruled out. A 2019 meta-analysis in The Lancet Diabetes and Endocrinology of 36 randomized controlled trials (8,480 women) found testosterone therapy significantly improved sexual function, desire, arousal, orgasm, and satisfaction compared with placebo or comparator. No FDA-approved testosterone product for women exists in the United States as of 2025; off-label use of compounded or low-dose male formulations is the current clinical approach.
• Switching OCP formulation: If SHBG elevation from an oral contraceptive is the cause, switching to a progestin-only method or a non-hormonal method raises free T without altering total T production.
• Treating the underlying cause: Hypopituitarism requires evaluation and likely estrogen plus androgen replacement; hypothalamic amenorrhea requires addressing the energy deficit.

PCOS, Menopause, and Other Female-Specific Conditions

PCOS Across the Life Span

PCOS is the approach case for free testosterone testing in women. Hyperandrogenemia is one of the three Rotterdam diagnostic criteria, and free testosterone is the most sensitive single biochemical marker. The 2023 International PCOS Guideline recommends calculated free testosterone, free androgen index, or bioavailable testosterone as preferred over total T for diagnosing biochemical hyperandrogenemia.

After menopause, the phenotype of PCOS shifts. Androgen levels tend to stay relatively higher than in age-matched women without PCOS, but the absolute values fall. Free testosterone monitoring in postmenopausal women with a PCOS history can clarify metabolic risk and guide decisions about testosterone therapy.

Menopause and Testosterone Therapy

Testosterone therapy in postmenopausal women is specifically for HSDD. Before prescribing, the clinician should establish a baseline free testosterone by equilibrium dialysis or calculated method. The target during therapy is a free T in the upper range of the premenopausal reference interval, not above it. Supraphysiological levels increase the risk of acne, hirsutism, and potentially adverse lipid changes.

The Menopause Society's 2022 position statement on testosterone therapy states: "There is sufficient evidence to support the use of testosterone therapy for the treatment of HSDD in postmenopausal women when administered at physiological premenopausal concentrations."

Female Pattern Hair Loss

Androgenic alopecia in women is frequently associated with elevated free testosterone and/or increased sensitivity of scalp follicles to dihydrotestosterone (DHT). Free T testing is part of the standard workup alongside DHEAS, 17-OHP, and thyroid function. Elevated free T with normal total T is a finding that would be missed without the specific test.

Hormonal Acne

Adult acne in women, especially along the jawline and chin, is driven partly by androgen stimulation of sebaceous glands. Free testosterone may be elevated even when total T is normal, particularly in women with low SHBG due to insulin resistance. Measuring free T is appropriate when adult acne is moderate to severe and not responding to topical therapy.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy

Testosterone levels rise substantially during pregnancy because placental production adds to ovarian and adrenal output. SHBG also rises sharply, so free testosterone may not change dramatically in absolute terms, but standard reference ranges for non-pregnant women do not apply. Free testosterone testing is not indicated for routine evaluation during pregnancy, and results cannot be interpreted against normal female reference intervals.

Virilization of a pregnant woman (clitoral enlargement, voice deepening, severe hirsutism appearing during gestation) is rare but a medical emergency requiring imaging to exclude a luteoma or androgen-secreting tumor.

Lactation

No specific free testosterone testing indication arises from lactation alone. Testosterone levels are generally low in lactating women due to sustained hyperprolactinemia suppressing the HPG axis. Women who report low libido during breastfeeding often have low estrogen as the primary driver. Free T may also be low. If testosterone therapy is being considered in a lactating woman, there are no human safety data on testosterone transfer into breast milk, and use is generally deferred until weaning.

Contraception Requirements for Androgen-Lowering Medications

Several drugs used to lower free testosterone carry teratogenic risk:

• Spironolactone: Associated with feminization of male fetuses in animal studies. The FDA label for spironolactone recommends discontinuation before attempting conception. Women of reproductive age taking spironolactone for hyperandrogenism should use reliable contraception.
• Flutamide and bicalutamide: Classified as teratogenic. Absolutely contraindicated in pregnancy. Reliable contraception is required throughout treatment.
• Finasteride: A 5-alpha reductase inhibitor sometimes used off-label for androgenic alopecia in women. Contraindicated in pregnancy; category X based on fetal genital malformation data. Women who are pregnant or may become pregnant should not handle crushed tablets.

Who This Test Is Right For (and Who Can Skip It)

Order Free Testosterone If You Are:

• A woman of any reproductive age with signs of androgen excess (hirsutism, persistent acne, androgenic alopecia, irregular cycles)
• Being evaluated for PCOS and total T is normal or borderline
• Postmenopausal with HSDD and being considered for testosterone therapy
• Currently on testosterone therapy and due for a 3- to 6-month monitoring check
• On combined oral contraceptives and experiencing symptoms that might reflect suppressed free T (low libido, fatigue) with a normal total T
• Being worked up for hypothalamic amenorrhea or hypopituitarism

Skip Free Testosterone (or Interpret with Caution) If You Are:

• Pregnant: standard ranges do not apply
• Using a direct immunoassay laboratory without access to equilibrium dialysis or a validated calculated method: push for a better assay before acting on the result
• Asymptomatic with no hormonal concern: this is not a screening test for well women

How to Prepare for the Test

• Timing: Draw in the early follicular phase (cycle days 2 to 5) for the most reproducible result in cycling women.
• Time of day: Testosterone peaks in the morning. Draw between 7 and 10 a.m. For consistency with reference ranges.
• Fasting: Not strictly required, but avoid a high-fat meal immediately before, as lipemia can interfere with some assays.
• Medications: Tell your clinician if you are taking oral contraceptives, biotin supplements (>5 mg/day can interfere with immunoassays), or any androgen-containing product.
• Method request: Ask the ordering clinician to specify equilibrium dialysis or validated calculated free testosterone, not a direct immunoassay.